# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Madhu Kumar initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and announces P...
Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistr...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and grante...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
HC Wainwright & Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $200 pric...